Viral hepatitis is a major global health issue since it is the seventh leading cause of death worldwide. Around half of hepatitis-related deaths reported are due to the hepatitis B virus infection, which is transmitted through blood and body fluids.
Hepatitis B virus (HBV) causes liver disease that leads to one million deaths throughout the world every year. Extensive research is going on to find the most effective, quick and accurate diagnostic measures followed by therapeutic solutions.
Hepatitis is considered as the seventh leading cause of death throughout the world, where half of the deaths occur due to hepatitis B viral infection. Early cost-effective diagnosis could help in treating the affected patients without any delay.
Dynavax Technologies Corporation (NASDAQ: DVAX) announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.